METASTATIC COLORECTAL CANCER

This study tests whether a combination of three drugs (adagrasib, cetuximab, and cemiplimab) can help control metastatic colorectal cancer in people whose tumors have a specific KRAS G12C mutation. About 31 adults who have already tried at least one prior treatment will receive t…

This study tests a new drug called JS212, given together with other cancer medicines, in people with metastatic colorectal cancer that has spread. The goal is to see if these combinations are safe and can shrink tumors. About 80 adults who have not had prior treatment for advance…

This study tests an experimental treatment for people with advanced cancers of the digestive tract, breast, ovary, or pancreas. Doctors take immune cells from a patient's tumor, grow the most powerful ones in a lab, and give them back along with a drug that helps the immune syste…

This study tests whether combining two drugs, fruquintinib and tislelizumab, can help people with a specific type of advanced colorectal cancer that has spread but not to the liver. The cancer type is called MSS/pMMR, which often does not respond well to standard immunotherapy. A…

This study tests an experimental drug called RBS2418 in 150 adults with advanced, metastatic colorectal cancer that has stopped responding to standard treatments. The drug works by helping the body's immune system recognize and attack cancer cells. Participants will receive eithe…

This study tests a new medicine, RPH-030, against an approved drug, Vectibix, for people with a certain type of advanced colorectal cancer. About 180 participants will receive either drug along with standard chemotherapy. The main goal is to see if the new drug works similarly in…

This study tests a drug called enfortumab vedotin in people with advanced colorectal or liver cancer that has not responded to other treatments. The goal is to see if the drug can shrink tumors. About 40 adults will take part, and the study is currently recruiting.

This study tests a new combination of chemotherapy drugs (FLIRT) plus a targeted therapy (bevacizumab) as a first treatment for people with a specific type of advanced colorectal cancer that has spread. The cancer must have a silenced MGMT gene and be microsatellite stable. The g…

This study tests an experimental drug called ART0380, taken as a pill, for people with advanced or metastatic solid tumors (cancers that have spread). The goal is to find the safest dose and see if it works alone or with standard chemotherapies (gemcitabine or irinotecan). About …

This study tests a drug called ivonescimab in 90 adults with metastatic colorectal cancer that has already been treated. The goal is to see if the drug can help control the cancer. Participants will receive the drug and be monitored for side effects and tumor response.

This study tests whether a new combination of three drugs (liposomal irinotecan, TAS102, and bevacizumab) can help people with advanced colorectal cancer that has stopped responding to standard treatments. The trial will enroll 50 adults whose cancer has spread or cannot be remov…

This study tests new drug combinations in 120 people with metastatic colorectal cancer that has spread. The goal is to see if these combinations can control the cancer longer and improve survival. Participants must have measurable tumors and not have had prior treatment for advan…

This study tests two different drug combinations for people with advanced colorectal cancer that has a specific gene change (RAS mutation) only detectable in a liquid biopsy. The goal is to see if one combination (bevacizumab plus chemotherapy) works better than the standard trea…

This early-stage trial tests a new treatment made from a patient's own immune cells (called TILs) for metastatic colorectal or prostate cancer. The goal is to see if repeated doses are safe and feasible. About 12 adults with advanced cancer that cannot be surgically removed will …

This early-phase study is testing a new treatment that delivers radiation directly to cancer cells in people with metastatic colorectal cancer that has not responded to standard therapies. The treatment uses a two-step process to attach a radioactive substance to tumor cells. The…

This study tests a new drug called precemtabart tocentecan, given alone or with bevacizumab, in about 1,020 people with metastatic colorectal cancer that has worsened after standard treatments. The goal is to see if it helps people live longer compared to the usual therapy (trifl…

This study tests an experimental drug called EMB-01 in people with advanced colorectal cancer that has come back or spread. About 54 participants will receive the drug on one of two schedules: once weekly, or once weekly for 6 weeks then every two weeks. The goal is to see which …

This study tests whether adding an immunotherapy drug (envafolimab) to a strong chemotherapy mix (mFOLFOXIRI) plus cetuximab works better than the standard cetuximab plus mFOLFOX6 for people with a specific type of advanced left-side colon cancer that has spread. About 198 adults…

This study tests a combination of up to four experimental drugs (retifanlimab, TriAdeno vaccine, N-803, and SX-682) in people with metastatic colorectal cancer that has spread and not responded to prior treatments. The goal is to see if the combination can shrink tumors or slow t…

This early-phase study tests a new drug called BBO-10203 in people with advanced solid tumors that have not responded to other treatments. The drug works by blocking a key cancer growth signal. The main goals are to find the safest dose and check for side effects, both when given…

This study tests whether adding two targeted drugs (sotorasib and panitumumab) to standard chemotherapy can help people with a specific genetic form of metastatic colorectal cancer (KRAS G12C) live longer without their cancer growing. About 450 adults who have not had prior treat…

This study tests whether adding an experimental drug called telisotuzumab adizutecan to standard chemotherapy can help people with metastatic colorectal cancer. About 390 adults will receive either the new combination or standard treatment. The goal is to see if the new drug shri…

This early-stage trial tests a new drug combination for people with advanced colorectal cancer that has spread and no longer responds to standard treatments. About 27 participants will receive ulixertinib along with cetuximab and/or encorafenib to find the safest dose. The goal i…

This study looks at how well a biosimilar version of bevacizumab (called Elovie) works and how safe it is when used as a first treatment for people with advanced colorectal cancer that cannot be removed by surgery. About 133 adults in Brazil will take part, and researchers will t…

This study tests whether adding a new immune-boosting drug (BNT314) to another immunotherapy (BNT327) and chemotherapy can help people with metastatic colorectal cancer that hasn't responded well to initial treatment. About 482 adults with a specific tumor type (MSS/pMMR) will ta…

This study is for people with metastatic colorectal cancer that has spread. It tests different targeted therapies or immunotherapies based on the specific genetic markers in each person's tumor. The goal is to see if these personalized treatments are safe and can shrink or contro…

This study tests a new combination of drugs for people with advanced colorectal cancer that has stopped responding to initial treatment. About 30 adults will receive a mix of chemotherapy and targeted therapy to see if it can slow or stop cancer growth. The goal is to find a bett…

This study tests a different chemotherapy drug (trifluridine/tipiracil) for people with metastatic colorectal or gastroesophageal cancer who have a genetic condition (DPD deficiency) that makes standard chemo very toxic. About 73 participants will receive this drug along with oth…

This study is testing whether a special PET scan can identify an aggressive form of colorectal cancer called CMS4 without needing tissue samples. About 45 people with colorectal cancer that has spread to the liver will receive the scan before surgery. If successful, this method c…

This study follows 1,000 people with metastatic colorectal cancer whose first chemotherapy stopped working. Researchers will watch which treatments doctors choose next and how well patients do. The goal is to learn about real-world treatment patterns and outcomes, not to test a n…

This study is gathering medical information and biological samples from 400 people with a specific genetic form of advanced colorectal cancer (BRAFV600E mutation). The goal is to learn how this cancer is currently treated in real-world settings and how long patients live. No new …

This study aims to create a mindfulness program designed for couples where one partner has metastatic colorectal cancer. Researchers will interview patients, their partners, and clinicians to understand their needs and preferences. The goal is to design a program that helps reduc…

This study looks at why a specific type of advanced colorectal cancer (with a BRAF V600E mutation) stops responding to targeted therapy. Researchers will collect tumor, blood, and stool samples from 30 patients before treatment and when the cancer progresses. The goal is to find …